These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28513868)

  • 1. HER2 assessment in locally advanced gastric cancer: comparing the results obtained with the use of two primary tumour blocks versus those obtained with the use of all primary tumour blocks.
    Xu C; Liu Y; Jiang D; Ge X; Zhang Y; Su J; Zeng H; Huang J; Ji Y; Hou J; Sun Y; Shen K; Liu T; Hou Y; Qin J
    Histopathology; 2017 Oct; 71(4):570-579. PubMed ID: 28513868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks.
    Ge X; Wang H; Zeng H; Jin X; Sujie A; Xu C; Liu Y; Huang J; Ji Y; Tan Y; Liu T; Hou Y; Qin J; Sun Y; Qin X
    Hum Pathol; 2015 Jun; 46(6):850-7. PubMed ID: 25863425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China.
    Xu C; Sun M; Jin M; Li Z; Qin R; Ren G; Sun W; Chen L; Luan L; Liu Y; Jiang D; Chen L; Luo R; Hou Y
    Diagn Pathol; 2022 Jun; 17(1):54. PubMed ID: 35765007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer.
    Zhang H; Wang Y; Wang Y; Wu D; Lin E; Xia Q
    Pathol Res Pract; 2020 Nov; 216(11):153229. PubMed ID: 33010699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance.
    Sheng WQ; Huang D; Ying JM; Lu N; Wu HM; Liu YH; Liu JP; Bu H; Zhou XY; Du X
    Ann Oncol; 2013 Sep; 24(9):2360-4. PubMed ID: 23788757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Image cytometric HER2 in gastric carcinoma: is a new algorithm needed?
    Ormenisan C; Wang J; Lawson D; Cohen C
    Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):414-9. PubMed ID: 23197004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
    Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
    Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.
    Saito T; Kondo C; Shitara K; Ito Y; Saito N; Ikehara Y; Yatabe Y; Yamamichi K; Tanaka H; Nakanishi H
    Pathol Int; 2015 Jun; 65(6):309-17. PubMed ID: 25828363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
    Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
    Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer.
    Ahn S; Hong M; Van Vrancken M; Lyou YJ; Kim ST; Park SH; Kang WK; Park YS; Jung SH; Woo M; Lee J; Kim KM
    Mol Diagn Ther; 2016 Aug; 20(4):375-83. PubMed ID: 27179810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment.
    Xu C; Liu Y; Jiang D; Ge X; Huang J; Su J; Zhang X; Lu S; Ji Y; Hou J; Liu T; Hou Y
    Aging (Albany NY); 2019 Nov; 11(22):10052-10060. PubMed ID: 31739285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.
    Grillo F; Fassan M; Sarocchi F; Fiocca R; Mastracci L
    World J Gastroenterol; 2016 Jul; 22(26):5879-87. PubMed ID: 27468182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.
    Huang SC; Ng KF; Lee SE; Chen KH; Yeh TS; Chen TC
    Gastric Cancer; 2016 Jan; 19(1):176-82. PubMed ID: 25512144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer.
    Xu C; Liu Y; Ge X; Jiang D; Zhang Y; Ji Y; Hou J; Huang J; Su J; Zeng H; Qin J; Hou Y
    Diagn Pathol; 2017 May; 12(1):41. PubMed ID: 28549444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
    Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
    Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK).
    Saito M; Yamashita K; Arimura Y; Kaneto H; Okuda H; Nojima M; Hagiwara T; Suzuki K; Adachi T; Goto A; Nakachi K; Yawata A; Yoshimoto M; Tanuma T; Adachi Y; Yamaoka S; Mizukoshi T; Kawayama M; Hamamoto Y; Shinomura Y
    Acta Oncol; 2016; 55(3):309-17. PubMed ID: 26757197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 in resected gastric cancer: Is there prognostic value?
    Fisher SB; Fisher KE; Squires MH; Patel SH; Kooby DA; El-Rayes BF; Cardona K; Russell MC; Staley CA; Farris AB; Maithel SK
    J Surg Oncol; 2014 Feb; 109(2):61-6. PubMed ID: 24122802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
    Hofmann M; Stoss O; Shi D; Büttner R; van de Vijver M; Kim W; Ochiai A; Rüschoff J; Henkel T
    Histopathology; 2008 Jun; 52(7):797-805. PubMed ID: 18422971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.